Development on CAR-T and TCR-T technologies for the treatment of solid tumors

Immunological therapies and their combination with gene therapy methods occupy one of the first places in the spectrum of new approaches to tumor therapy. The development of new methods of CAR-T therapy is at the junction of research in such fields as immunology, biotechnology, genetics and medicine in general. The Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation has developed an innovative technology for the production of CAR-T lymphocytes, characterized by high efficiency, low cost and reduced time to obtain the final product. Preclinical testing complexes of two products for CAR-T therapy of solid tumors carrying chimeric antigenic receptors for the tumor-specific antigen CA-125 have been fully completed (clinical nosology: ovarian, lung, pancreatic cancer, etc.) and cancer-embryonic antigen (REA) (colon cancer, stomach cancer, pancreas, etc.). The conducted preclinical studies proved a pronounced specific cytotoxic effect against tumor cells expressing the corresponding antigens, allowed to determine the therapeutic index of drug doses and showed the prospect of further development and the possibility of clinical stages of research.